TITLE

Predicted Coronary Heart Disease Risk in Croatian HIV Infected Patients Treated with Combination Antiretroviral Therapy

PUB. DATE
March 2011
SOURCE
Collegium Antropologicum;Mar2011, Vol. 35 Issue 1, p115
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
60943122

 

Related Articles

  • Is Primary Mycobacterium avium Complex Prophylaxis Necessary in Patients with CD4 <50 Cells/μL Who Are Virologically Suppressed on cART? Yangco, Bienvenido G.; Buchacz, Kate; Baker, Rose; Palella, Frank J.; Armon, Carl; Brooks, John T. // AIDS Patient Care & STDs;Jun2014, Vol. 28 Issue 6, p280 

    We analyzed 369 patients with no prior Mycobacterium avium complex (MAC) infection and CD4 <50 cells/μL (baseline), while on combination antiretroviral therapy(cART), for incidence rates of primary MAC infection during the 6 months after baseline, by prophylaxis status. Of participants...

  • Efficacy and Safety of Emtricitabine vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients: A Randomized Trial. Saag, Michael S.; Cahn, Pedro; Raffi, François; Wolff, Marcelo; Pearce, Daniel; Molina, Jean-Michel; Powderly, William; Shaw, Audrey L.; Mondou, Elsa; Hinkle, John; Borroto-Esoda, Katyna; Quinn, Joseph B.; Barry, David W.; Rousseau, Franck // JAMA: Journal of the American Medical Association;7/14/2004, Vol. 292 Issue 2, p180 

    Context Emtricitabine is a new, once-daily nucleoside reverse transcriptase inhibitor (NRTI) with potent activity against human immunodeficiency virus (HIV). Objective To assess the efficacy and safety of emtricitabine as compared with stavudine when used with a background regimen of didanosine...

  • Brain structural and functional recovery following initiation of combination antiretroviral therapy. Becker, James; Cuesta, Pablo; Fabrizio, Melissa; Sudre, Gustavo; Vergis, Emanuel; Douaihy, Antoine; Bajo, Ricardo; Schubert, Allie; Lopez, Oscar; Parkkonen, Lauri; Maestu, Fernando; Bagic, Anto // Journal of NeuroVirology;Oct2012, Vol. 18 Issue 5, p423 

    NeuroAIDS persists in the era of combination antiretroviral therapies. We describe here the recovery of brain structure and function following 6 months of therapy in a treatment-naive patient presenting with HIV-associated dementia. The patient's neuropsychological test performance improved and...

  • Dealing with sparse data in predicting outcomes of HIV combination therapies. Bogojeska, Jasmina; Bickel, Steffen; Altmann, André; Lengauer, Thomas // Bioinformatics;Sep2010, Vol. 26 Issue 17, p2085 

    Motivation: As there exists no cure or vaccine for the infection with human immunodeficiency virus (HIV), the standard approach to treating HIV patients is to repeatedly administer different combinations of several antiretroviral drugs. Because of the large number of possible drug combinations,...

  • Risk of AIDS-Defining Cancers Among HIV-1–Infected Patients in France Between 1992 and 2009: Results From the FHDH-ANRS CO4 Cohort. Hleyhel, Mira; Belot, Aurélien; Bouvier, Anne Marie; Tattevin, Pierre; Pacanowski, Jérôme; Genet, Philippe; De Castro, Nathalie; Berger, Jean-Luc; Dupont, Caroline; Lavolé, Armelle; Pradier, Christian; Salmon, Dominique; Simon, Anne; Martinez, Valérie; Costagliola, Dominique; Grabar, Sophie // Clinical Infectious Diseases;Dec2013, Vol. 57 Issue 11, p1638 

    Although the incidence of AIDS-defining cancers has decreased over time, the risk remained high in 2005–2009. Patients with stably restored immunity on combination antiretroviral therapy had an elevated risk for Kaposi sarcoma and risk similar to that of the general population for...

  • Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects. Dieye, Tandakha N.; NDiaye, Birahim P.; Dieng, Alle B.; Fall, Marema; Britain, Nathaniel; Vermaak, Samantha; Camara, Makhtar; Diop-Ndiaye, Halimatou; Ngom-Gueye, Ndeye Fatou; Diaw, Papa A.; Toure-Kane, Coumba; Sow, Papa S.; Mboup, Souleymane; McShane, Helen // PLoS ONE;Jun2013, Vol. 8 Issue 6, p1 

    Tuberculosis (TB) is a global public health problem exacerbated by the HIV epidemic. Here we evaluate a candidate TB vaccine, MVA85A, in a Phase I study in HIV-infected adults in Senegal. 24 patients were enrolled: Group 1∶12, antiretroviral therapy (ART) naïve, adults, with CD4 counts...

  • A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men. Margaret May; Jonathan A C Sterne; Martin Shipley; Eric Brunner; Ralph d’Agostino; Peter Whincup; Yoav Ben-Shlomo; Andrew Carr; Bruno Ledergerber; Jens D Lundgren; Andrew N Phillips; Joseph Massaro; Matthias Egger // International Journal of Epidemiology;Dec2007, Vol. 36 Issue 6, p1309 

    Background Many HIV-infected patients on highly active antiretroviral therapy (HAART) experience metabolic complications including dyslipidaemia and insulin resistance, which may increase their coronary heart disease (CHD) risk. We developed a prognostic model for CHD tailored to the changes in...

  • Metabolic-Inflammatory Changes, and Accelerated Atherosclerosis in HIV Patients: Rationale for Preventative Measures. De Lorenzo, F.; Collot-Teixeira, S.; Boffito, M.; Feher, M.; Gazzard, B.; McGregor, J. L. // Current Medicinal Chemistry;2008, Vol. 15 Issue 28, p2991 

    Human immunodeficiency virus (HIV)-infected patients are at a significantly higher risk from coronary heart diseases (CHD) and myocardial infarction (MI) compared to gender- and age-matched non-infected individuals. Combination antiretroviral therapy (cART) has transformed a fatal illness into a...

  • Endothelial Function in HIV-Infected Persons. Solages, Anthony; Vita, Joseph A.; Thornton, David J.; Murray, Jessica; Heeren, Timothy; Craven, Donald E.; Horsburgh, Jr., C. Robert // Clinical Infectious Diseases;5/1/2006, Vol. 42 Issue 9, p1325 

    Background. Several reports have suggested an increased risk of coronary disease in human immunodeficiency virus (HIV)-infected patients receiving protease inhibitors (PIs). Impaired endothelium-dependent vasodilation is a putative surrogate marker of coronary atherosclerotic disease. Methods....

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics